Guidelines & Consensus
A Multimodal Framework to Guide Solid Tumor Indications for Natural Killer Cell-Based Therapy
Chiossone et alEuropean Journal of Immunology
While T cell-based immunotherapies have demonstrated substantial clinical efficacy in hematological malignancies, their translation to solid tumors faces persistent challenges. Natural killer (NK) cell therapies represent an alternative modality capable of targeting and killing malignant cells independently of MHC class I expression and neoantigen presentation. To identify solid tumor indications with the highest likelihood of therapeutic response, investigators implemented a multimodal framework incorporating immunohistochemical evaluation, a systematic review of clinical trials, and large-scale transcriptomic analyses.
Immunohistochemical assessment confirmed that NK cells penetrate diverse tumor histologies, demonstrating the highest density of infiltration within kidney tumors. Concurrently, a systematic analysis of 177 completed and ongoing clinical trials demonstrated heterogeneous clinical outcomes across solid tumor types, with no single intervention strategy or disease indication demonstrating clear therapeutic superiority.
To refine candidate selection, transcriptomic profiling was conducted across more than 10,000 samples from The Cancer Genome Atlas (TCGA) to evaluate baseline NK cell infiltration levels, cytotoxic fitness signatures, and the surrounding tumor microenvironment composition. This analysis identified kidney renal cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, cervical and endocervical cancers, and mesothelioma as priority candidates. These findings provide an evidence-based roadmap to optimize trial design and clinical indication selection for investigational NK cell platforms in solid oncology.
Key Takeaways
- Immunohistochemical profiling demonstrated that natural killer cells infiltrate multiple solid tumor malignancies, with the highest abundance observed in kidney tumors.
- A systematic review of 177 clinical trials revealed variable clinical efficacy across solid tumor indications, identifying no clearly superior tumor type or specific natural killer cell intervention.
- Transcriptomic analysis of more than 10,000 TCGA samples identified kidney renal cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, cervical and endocervical cancers, and mesothelioma as the most promising targets based on natural killer cell infiltration, cytotoxic fitness, and microenvironment characteristics.
Read the original sourceEuropean Journal of Immunology
